Where does Levicept Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Levicept Ltd ranks #41,403 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Levicept Ltd hold?

Levicept Ltd holds 6 US utility patents granted between 2017 and 2025, spanning 4 technology areas.

What is Levicept Ltd's Innovation Score?

Levicept Ltd has an Innovation Score of 24.2 out of 100 (14th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Levicept Ltd's patent grant rate increasing or decreasing?

Levicept Ltd's recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Levicept Ltd's patents?

Levicept Ltd's patents average 11.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Levicept Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Levicept Ltd

Q: What technology areas does Levicept Ltd focus on?

Levicept Ltd's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Levicept ranks #41,403 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#41,403
of 49,997 US assignees by volume: 14th percentile
by Innovation Score (24.2/100): 11.8
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R41403 · Foreign Corporation #41,403 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #41,403/49,997
PHOTO-FINISH LenovoEMC
CPC-NARROW A61P · 4 areas
INNOV-THIN 24.2/100
CLAIMS-PAR 11.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: LenovoEMC Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Levicept · this assignee

24
3D Lighting… · lowest

7

What this shows Levicept's Innovation Score is 24.2/100 (14th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Levicept's grants concentrate

Levicept Ltd is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). By volume, Levicept sits between LenovoEMC Limited and Li-Cycle Corp..

Levicept's three-year grant acceleration

Levicept Ltd shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Lenovoemc

6
Lenz Therapeutics

6
Lenze SE

6
Leo Schachter Dia…

6
Lewis Bolt & Nut

6
Lex Submersible P…

6
Li Creative

6
Li-cycle

6
Levicept ◀

6

What this shows Levicept holds 6 patents at rank #41,435, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Levicept

By rank, the assignees closest to #41,435 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Levicept's primary technology class.

Levicept's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 14th percentile higher than 14% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Levicept Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	16.7%
2018	1	16.7%
2020	1	16.7%
2021	1	16.7%
2022	1	16.7%
2025partial year	1	16.7%

Which technologies does Levicept Ltd patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07K - Peptides 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#41,403

of 49,997 tracked assignees

Innovation Score

24.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Levicept Ltd's patent record in context - here's where to go next.

Levicept Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #41,403 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Levicept Ltd against LenovoEMC Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.